no more compounding glp 1 drugs Compounded GLP-1 ban: What providers need to know Decoding GLP-1 Weight Loss Medications

In June 2024, Novo Nordisk and Eli Lilly dominated the obesity market, with Novo Nordisk generating $6.3 billion and Eli Lilly $2.3 billion in sales from their weight-loss drugs in Q1 2024

Simultaneously, sympathetic nervous system activity measured by HR variability and the rate-pressure-product were also elevated, and increases in HR, systolic BP and sympathetic nervous system activity were still observed even with a concomitant L-NMMA-infusion [38]

Due to the expression of GLP-1 receptors in testicular cells, they can raise testosterone levels and increase sperm motility and metabolism (101)

The weight loss achieved varies by medication: liraglutide typically produces 5-8% weight loss, semaglutide approximately 15%, and tirzepatide up to 21% of initial body weight

Zealand Pharma has completed Phase 1 testing but has not announced a Phase 3 start date, citing the need for "formulation improvements to increase bioavailability and reduce skin irritation." A realistic timeline: Phase 3 could start late 2026, with 52-week data by mid-2028 and an FDA submission in late 2028 at the earliest

Natural compounds increasing attention owing to their safety, few side effects, and definite curative effects mainly involves improved insulin sensitivity and insulin resistance, inhibited activity of alpha-glucosidase, antioxidant activity, anti-inflammatory, regulation of gut microbiota (12)